肥胖与宫颈癌前病变及宫颈癌治疗后风险的相关性
这项回顾性队列研究纳入10614例因宫颈癌前病变接受切除治疗的25岁及以上患者,按体重指数(BMI)分组,评估治疗后2年内宫颈上皮内瘤变3级及以上(CIN3+)和癌的风险。结果显示肥胖患者治疗后CIN3+和癌风险均高于正常体重者,且随肥胖等级增加呈上升趋势。
要点
- 肥胖患者切除治疗后2年CIN3+风险为8.65%,正常体重者为5.57%。
- 肥胖患者2年癌风险为0.79%,正常体重者为0.29%。
- BMI与CIN3+风险关联的风险比从超重者的1.19升至III级肥胖者的1.89。
核心结论
- 肥胖患者因宫颈癌前病变接受切除治疗后,残留或复发性病变风险更高,可能归因于切除不彻底。
研究设计与样本
- 回顾性队列研究,纳入2017年1月起至2023年2月随访期间,年龄25岁及以上、因宫颈上皮内瘤变2级或3级或原位腺癌接受切除治疗的患者,排除BMI缺失、切除时发现癌、以子宫切除术替代切除或缺少有效转诊筛查记录者,共10614例。
- BMI分组为体重过轻/正常(<25 kg/m2)、超重(25至<30 kg/m2)和肥胖(≥30 kg/m2),并按肥胖分级(I-III级)进一步分类。
- 采用Kaplan-Meier法计算2年CIN3和癌(合并为CIN3+)风险,采用Cox比例风险回归分析BMI与CIN3+的多变量校正关联,校正因素包括治疗时年龄、种族和民族以及治疗类型。
主要发现
- 10614例患者中,680例(6.4%)发生治疗后CIN3+,其中大多数(91%)在治疗2年内发生。
- 肥胖者2年CIN3+风险为8.65%(95% CI,7.6%-9.9%),正常体重者为5.57%(95% CI,4.9%-6.3%);肥胖者2年癌风险为0.79%(95% CI,0.5%-1.2%),正常体重者为0.29%(95% CI,0.2%-0.5%)。
- BMI与治疗后CIN3+风险关联的风险比从超重者的1.19(95% CI,1.0-1.4)升至III级肥胖者的1.89(95% CI,1.4-2.6),趋势P值<.0001。
- 癌风险呈现相似趋势,超重者风险比为1.62(95% CI,0.8-3.3),III级肥胖者为3.50(95% CI,1.3-9.3),趋势P值=.016。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individuals with obesity have an increased risk of cervical cancer, in part related to challenges associated with cervical sampling and visualization that result in missed detection of cervical precancers. The influence of obesity on the effectiveness of excisional treatment of detected cervical precancers and posttreatment disease risk is unknown. OBJECTIVE: The aim of this study was to evaluate posttreatment risks of cervical precancer and cancer by body mass index (BMI). STUDY DESIGN: This retrospective cohort study included individuals aged 25 years and older undergoing excisional treatment for cervical precancer, either cervical intraepithelial neoplasia (CIN) grade 2 or 3 or adenocarcinoma in situ as of January 2017 with follow-up through February 2023. Patients were excluded if they were missing BMI, had cancer upon excision or had hysterectomy in lieu of excision, or were missing a valid referral screening visit. We categorized BMI as follows: underweight/normal (<25 kg/m2), overweight (25 to <30 kg/m2), and obesity (≥30kg/m2), as well as by class (I-III) of obesity. We calculated 2-year risks of CIN3 and cancer (combined as CIN3+) using Kaplan Meier methods and evaluated multivariable adjusted associations of BMI with CIN3+ using Cox Proportional Hazards regression analyses, accounting for age at treatment, race and ethnicity, and treatment type. RESULTS: Among 10,614 patients, a total of 680 (6.4%) developed post-treatment CIN3+; most (91%) within 2 years of treatment. Two-year CIN3+ and cancer risks were highest in those with obesity (8.65%, 95% CI, 7.6%-9.9% and 0.79%, 95% CI, 0.5%-1.2%, respectively) and lowest in those with normal weight (5.57%, 95% CI, 4.9%-6.3% and 0.29%, 95% CI, 0.2%-0.5%, respectively). Hazard ratios measuring associations of BMI with risk of posttreatment CIN3+ ranged from 1.19 (95% CI, 1.0-1.4) among those with overweight to 1.89 (95% CI, 1.4-2.6) among those with class III obesity (P-trend<.0001). A similar trend was observed for cancer, from 1.62 (95% CI, 0.8-3.3) for overweight and 3.50 (95% CI, 1.3-9.3) for class III obesity (P-trend=.016). CONCLUSION: Patients with obesity undergoing excisional treatment for cervical precancer have a higher risk of residual or recurrent disease, likely due to incomplete excision.
引用
- Clarke MA, Befano B, Wentzensen N, et al. Associations of obesity with post-treatment risks of cervical precancer and cancer. Am J Obstet Gynecol. 2024. PMID: 39647654. doi:10.1016/j.ajog.2024.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。